Streetbeat News

Products Services

HRTX

Heron Therapeutics, Inc. (NASDAQ:HRTX) has entered into a five-year distribution partnership with CrossLink Life Sciences, LLC to enhance the promotion and sales network for ZYNRELEF, an extended-release solution for orthopedic indications. The partnership will add approximately 650 representatives to Heron's sales network over the next year, with CrossLink being compensated on a fixed-fee per vial basis.

Portfolio Pulse from Charles Gross

January 07, 2024 | 10:16 pm

NIU

Niu Technologies (NASDAQ:NIU) reported a slight decrease in sales volume for Q4 and FY23 compared to the previous year. Q4 sales were 137,476 units versus 138,279 units YoY, and FY23 sales were 709,802 units versus 831,593 units YoY. Despite a slow recovery in the China market, NIU's mass-premium products grew to 75% of domestic sales. Internationally, sales were bolstered by retail partnerships with BestBuy in the US and MediaMarkt in Europe, with offline retail sales making up over 80% of micro-mobility sales. The company cautions that sales volume is just one measure of performance and not a definitive indicator of financial results.

Portfolio Pulse from Benzinga Newsdesk

January 07, 2024 | 8:22 pm

AAPL

AMZN

GOOGL

MSFT

Apple Inc. (AAPL) faces multiple challenges including a potential fifth consecutive quarter of sales decline, late entry into AI, and regulatory scrutiny of the App Store. Bloomberg's Mark Gurman suggests that while iPhone sales, especially in China, are concerning, they are not Apple's biggest challenge. Apple's AI tools are expected to be unveiled at the WWDC in June but may lag behind competitors like Microsoft, Alphabet, and Amazon. The App Store is also facing regulatory challenges in the EU, which could lead to revenue decline and increased competition.

Portfolio Pulse from Shanthi Rexaline

January 07, 2024 | 8:20 pm

IDYA

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) reported a strong balance sheet with $511.1M in cash and securities as of September 30, 2023. The company expects the funds, including $134.7M from follow-on financing and $10M receivable from GSK, to support operations into 2028. IDEAYA announced updates at the J.P. Morgan Healthcare Conference, including international patient enrollment in a Phase 2/3 trial for darovasertib and crizotinib, and various clinical program updates for 2024. The company is also advancing collaborations with GSK and targeting IND submissions and new development candidate nominations in 2024.

Portfolio Pulse from Benzinga Newsdesk

January 07, 2024 | 8:15 pm

VRTX

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) provided updates on its pipeline and business operations before the 42nd Annual J.P. Morgan Healthcare Conference. Key highlights include the launch of CASGEVY in the U.S., UK, and Bahrain, completion of pivotal studies for cystic fibrosis treatments, and progress in studies for sickle cell disease, acute pain, peripheral neuropathic pain, kidney disease, type 1 diabetes, and myotonic dystrophy. Vertex also revised patient estimates for cystic fibrosis and sickle cell disease. The company expects to share study results and advance various programs in 2024.

Portfolio Pulse from Benzinga Newsdesk

January 07, 2024 | 8:06 pm

ASND

Specialised Therapeutics Asia has signed an exclusive agreement with Ascendis Pharma to distribute and commercialize three endocrinology therapies in Australia and select South-East Asia countries. The therapies include SKYTROFA for paediatric growth hormone deficiency, YORVIPA for hypoparathyroidism, and TransCon CNP for achondroplasia. The agreement covers Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam. Two of the products are already internationally approved.

Portfolio Pulse from Charles Gross

January 07, 2024 | 7:34 pm

AKYA

Akoya Biosciences, Inc. (NASDAQ:AKYA) has announced the deployment of the MaxFuse algorithm, co-developed with Dr. Garry Nolan's lab at Stanford University, for multiomic integration of spatial and single-cell data on the Enable Medicine platform. Dr. Nolan is a co-founder and board member of Akoya Biosciences, which specializes in spatial biology and collaborates with Enable Medicine, a provider of AI-powered biological insights.

Portfolio Pulse from Charles Gross

January 07, 2024 | 4:06 pm

AKYA

TMO

Akoya Biosciences, Inc. (AKYA) has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc. (TMO) to market a spatial multiomics workflow. This collaboration combines Akoya's PhenoImager systems and PhenoCode reagents with Thermo Fisher's ViewRNA In Situ Hybridization Assays. The partnership aims to provide a comprehensive suite of multiomic solutions to enhance the understanding of tumor progression and biomarker development.

Portfolio Pulse from Charles Gross

January 07, 2024 | 4:05 pm

HEMP

During Dry January, the cannabis industry is offering alternatives to alcohol with new products. Cheech Marin and Tommy Chong have partnered with NorthEast Extracts LLC to launch their cannabis products in New York. BioWellnessX has introduced a premium THCa flower wholesale line. WhistlePig Whiskey has released a non-alcoholic, terpene-infused cocktail with proceeds benefiting Turning Tables. Illicit Gardens and Monopoly Melts have collaborated on Hash Holes, a series of craft pre-rolls. Hemp, Inc. is capitalizing on the demand for hemp-derived products, while Kiva Confections' Camino gummies offer a cost-effective and healthy alternative to cocktails.

Portfolio Pulse from Joana Scopel

January 07, 2024 | 3:53 pm

LCID

NIO

RIVN

TSLA

VWYAG

Argus analyst Bill Selesky maintains a bullish stance on Tesla, Inc. (NASDAQ:TSLA), predicting a 33% stock rally as he expects the company's growth to reaccelerate in 2024. Selesky cites Tesla's artificial intelligence in manufacturing and factory utilization as a significant competitive advantage. He also notes Tesla's current leadership in the EV market and potential for increased market share. Despite challenges faced by competitors like Ford (NYSE:F), General Motors (NYSE:GM), Toyota (NYSE:TM), Volkswagen (OTC:VWYAG), Nio (NYSE:NIO), Lucid Motors (NASDAQ:LCID), and Rivian (NASDAQ:RIVN), Tesla is poised for growth. Argus has set a $316 price target for Tesla stock.

Portfolio Pulse from Shanthi Rexaline

January 07, 2024 | 2:07 pm